Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN) announced the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, scheduled for November 14-19, 2024, in Washington, D.C. The company's featured plenary presentation, in collaboration with Johns Hopkins University, will showcase a urinary biomarker panel for guiding precision management of Lupus Nephritis. Additional abstracts highlight Exagen's research on novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, aimed at improving diagnostic sensitivity of the AVISE CTD platform.

The accepted abstracts cover topics such as predicting histologically active Lupus Nephritis, validating T Cell-bound C4d and T Cell Autoantibodies for SLE diagnosis, and exploring autoantibodies in seronegative rheumatoid arthritis. These presentations demonstrate Exagen's commitment to innovative research in rheumatologic care.

Positive

• Acceptance of five abstracts at a major rheumatology conference, showcasing Exagen's research prowess
• Collaboration with Johns Hopkins University on a plenary presentation, potentially enhancing company credibility
• Development of novel biomarkers for Lupus and rheumatoid arthritis, potentially improving diagnostic accuracy
• Potential improvement in the diagnostic sensitivity of the AVISE CTD platform, which could lead to increased market adoption

Negative

• None.

CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis, addressing a critical need for rheumatologists. Additional abstracts highlight Exagen’s innovative research on novel T Cell biomarkers for Lupus and anti-RA33 autoantibodies for rheumatoid arthritis, both of which will significantly improve diagnostic sensitivity of the AVISE CTD platform.

“Exagen’s commitment to innovative research is showcased in our abstracts and validates our continued efforts to bring novel biomarkers to the forefront of rheumatologic care,” said Dr. Andrew Concoff, Chief Innovation Officer of Exagen. “We look forward to sharing our findings with the rheumatology community, with the goal of furthering patient care.”

Below is the list of accepted abstracts, with links to each:

Plenary Session in Collaboration with Johns Hopkins

Plenary Session | Presented by Andrea Fava | Abstract #1642
Title: A Urinary Biomarker Panel to Predict the Probability of Histologically Active Lupus Nephritis
Session Title: Plenary II
Session Date and Time: Sunday, November 17^th, 2024, from 9:00 a.m. – 9:15 a.m. ET

Novel Biomarker Development Abstracts

Poster Presentation | Presented by Vasileios Kyttaris | Abstract #1490
Title: Multi-centered Clinical Validation of T Cell-bound C4d (TC4d) and T Cell Autoantibodies (TIgG and TIgM): Sensitive and Specific Biomarkers of SLE with Enhanced Accuracy Compared to Conventional SLE Tests
Session Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster II
Session Date and Time: Sunday, November 17^th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Poster Presentation | Presented by Andrew Concoff| Abstract #2233
Title: Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis
Session Title: RA – Diagnosis, Manifestations, & Outcomes, Poster III
Session Date and Time: Monday, November 18^th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Poster Presentation | Presented by Andrew Concoff| Abstract #2232
Title: Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Session Title: RA – Diagnosis, Manifestations, & Outcomes, Poster III
Session Date and Time: Monday, November 18^th, 2024, from 10:30 a.m. – 12:30 p.m. ET

Clinical Evidence Reinforcing CB-CAPs Superior Performance Compared to Conventional Tests

Poster Presentation | Presented by Andrew Concoff| Abstract #0608
Title: Systematic Analysis Demonstrates the Added Value of CB-CAPs to SLE Diagnosis in a Large Validation Cohort
Session Title: SLE – Diagnosis, Manifestations, & Outcomes, Poster I
Session Date and Time: Saturday, November 16^th, 2024, from 10:30 a.m. – 12:30 p.m. ET

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management. For more information, visit Exagen.com or follow @ExagenInc on X.

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products; the potential utility and effectiveness of Exagen’s services and testing solutions; updates to be made to AVISE^® CTD; potential shareholder value and growth and 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; changes in laws and regulations related to Exagen’s regulatory requirements; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525

FAQ

What is the significance of Exagen's (XGN) abstracts being accepted at ACR Convergence 2024?

The acceptance of five abstracts at ACR Convergence 2024 demonstrates Exagen's (XGN) strong research capabilities and commitment to innovation in autoimmune testing. It provides an opportunity for the company to showcase its advancements in biomarker development and diagnostic tools to the rheumatology community.

What new biomarkers is Exagen (XGN) presenting at ACR Convergence 2024?

Exagen (XGN) is presenting research on a urinary biomarker panel for Lupus Nephritis, novel T Cell biomarkers for Lupus, and anti-RA33 autoantibodies for rheumatoid arthritis. These biomarkers aim to improve diagnostic sensitivity and guide precision management in autoimmune diseases.

When and where is ACR Convergence 2024 taking place?

ACR Convergence 2024 is scheduled to take place from November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.

What is the focus of Exagen's (XGN) plenary presentation at ACR Convergence 2024?

Exagen's (XGN) plenary presentation, in collaboration with Johns Hopkins University, focuses on a urinary biomarker panel that has the potential to guide precision management of Lupus Nephritis, addressing a critical need for rheumatologists.